2nd Jun 2008 07:00
CELSIS INTERNATIONAL PLC
NOTIFICATION OF RESULTS
2 June 2008: Celsis International plc, the life sciences products and laboratory services company, will announce its preliminary results for the year ended 31 March 2008 on Wednesday 18 June 2008.
There will be a presentation to analysts on the day at 9.30am, held at Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London, WC2A 1PB. There will also be a conference call available, for more information please contact Claire Rowell on +44 (0)207 269 7285.
|
Enquiries: |
|
|
Celsis International plc |
Tel: 01223 598 428 |
|
Jay LeCoque, Chief Executive Officer |
|
|
Jenny Woolway, Corporate Communications |
|
|
Financial Dynamics |
Tel: 020 7831 3113 |
|
Lara Mott |
|
|
Ben Atwell |
Notes to editors
Celsis International plc
Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas; rapid detection, analytical and drug development services and ADME-Tox in vitro technologies. The company is listed on the London Stock Exchange (CEL.L)
Each division of Celsis International plc has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical and biopharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing. Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical and biotechnology industries. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver.
Further information can be found on its website at www.celsis.com.
Related Shares:
Celadon Pharmaceuticals